A report of findings from the American Society of Clinical Oncology’s third annual National Cancer Opinion Survey.
ALEXANDRIA, Va. — The American Society of Clinical Oncology (ASCO) today presented Representatives Ben Ray Luján (NM-3) and Gus Bilirakis (FL-12) with its annual Congressional Leadership Award in recognition of the lawmakers' exceptional, bipartisan commitment to supporting cancer research and treatment. The ASCO award honors Members of Congress who are leading champions for patients and survivors of cancer, their families, and their cancer care teams.
ALEXANDRIA, Va. — Roughly one in five young adults uses e-cigarettes daily or recreationally, and nearly one in four believes the products are harmless and not addictive, according to findings from the American Society of Clinical Oncology (ASCO)’s third annual National Cancer Opinion Survey. This comes after the Centers for Disease Control and Prevention (CDC) issued the results from its National Youth Tobacco Survey earlier this month, reporting that e-cigarette use among pre-teens and teens is on the rise. It is also despite warnings from the U.S. Surgeon General that e-cigarettes (also known as vapes) contain addictive and harmful or potentially harmful ingredients, including nicotine; lead and other heavy metals; and flavorants such as diacetyl, a chemical linked to serious lung disease. Amid public debate over banning flavored e-cigarettes, the ASCO survey also found that nearly three in 10 young adults think flavored e-cigarettes are less damaging to a person’s health than non-flavored ones. In addition, nearly seven in 10 Americans support raising the legal age to purchase e-cigarettes from 18 to 21.
“We applaud the National Academies of Sciences, Engineering, and Medicine for its recommendations on cancer control in the United States. The report examines the oncology community’s efforts over the past 10 years and lays out a comprehensive path for addressing the complex issues facing the entire cancer care continuum, from government agencies to the individual physician.
Chicago — In an effort to advance cancer data sharing and improve the quality and coordination of patient care, three of the nation’s leading health and technology organizations have established a core set of data elements and recommended technical specifications (the Minimal Common Oncology Data Elements, or “mCODE”) that are essential for capturing and reporting the characteristics, treatments, and outcomes of every cancer patient and should be contained in each patient’s electronic health record (EHR). The mCODE™ initiative, a collaboration between the American Society of Clinical Oncology, Inc. (ASCO®), its wholly owned nonprofit subsidiary CancerLinQ LLC, the MITRE Corporation, and the Alliance for Clinical Trials in Oncology Foundation (Alliance Foundation), released the initial set of common cancer data standards and specifications today at ASCO’s 2019 Annual Meeting in Chicago and published them online at mCODEinitiative.org.
“ASCO strongly supports this strong, bipartisan bill that would raise the federal age for purchasing tobacco products, electronic cigarettes, and alternative nicotine products from 18 to 21 nationwide. This legislation represents an important federal policy change needed to address the ongoing public health epidemic from tobacco use in the United States.
ALEXANDRIA, Va. — A new study published today in the Journal of Oncology Practice (JOP) reveals the findings of a 2018 American Society of Clinical Oncology (ASCO) Oncology Workforce survey on oncologists’ perceptions and practice behaviors related to diet, physical activity, and weight management in people with cancer — during and after active treatment. The research was also presented today at the American Institute for Cancer Research (AICR) 2019 Research Conference, Diet, Obesity, Physical Activity and Cancer — Beyond the Blueprint.
Today at the National Press Club, the American Society of Clinical Oncology (ASCO) announced a new task force aimed at reducing disparities and improving outcomes for patients and survivors of cancer who live in rural communities. The new “Rural Cancer Care Task Force” will identify opportunities to close the rural cancer care gap and implement strategies to improve rural cancer care in the United States.
The American Society of Clinical Oncology (ASCO) and ASCO's Conquer Cancer Foundation proudly recognize the winners of ASCO's Special Awards, the Society's highest honors, and Conquer Cancer's Women Who Conquer Cancer Mentorship Awards. The recipients of these awards have worked to transform cancer care around the world. ASCO will recognize this year’s awardees at its 2019 Annual Meeting.
ALEXANDRIA, Va.—The American Society of Clinical Oncology (ASCO) announced today that it is seeking applications for research grants for projects that use data from CancerLinQ Discovery®, an offering of ASCO's CancerLinQ® initiative, as a source. CancerLinQ Discovery® provides curated sets of de-identified data from cancer patients to academic researchers, government agencies, and others in the oncology community to generate practical knowledge that will improve cancer care.
"Rates of obesity-related cancers are rising most sharply among young adults, but this study should serve as a wake-up call to all Americans – young and old alike – that obesity is linked to an increased risk of common cancers. If current trends continue, it is estimated that obesity will lead to more than 500,000 additional cases of cancer each year in the United States by 2030."
ALEXANDRIA, Va. — Over the past year, major research advances provided new treatment options for patients with rare, difficult-to-treat cancers. In recognition of these achievements, the American Society of Clinical Oncology (ASCO) names “Progress in Treating Rare Cancers” as the Advance of the Year. To continue the forward momentum, ASCO also debuts its list of Research Priorities to accelerate progress against cancer. These and additional milestones in cancer research are featured in ASCO’s annual Clinical Cancer Advances report, released today.
Statement from American Society of Clinical Oncology (ASCO) President Monica M. Bertagnolli, MD, FACS, FASCO, on the American Cancer Society Cancer Facts and Figures 2019 Report
Alexandria, VA. & Chicago – The American Society of Clinical Oncology, Inc. (ASCO) and Tempus announced today an agreement to support research sites participating in ASCO’s Targeted Agent and Profiling Utilization (TAPUR™) Study. The TAPUR Study is a prospective, non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of Food and Drug Administration-approved, targeted anticancer drugs that are used for the treatment of patients who have both advanced cancer and a potentially actionable genomic alteration. Tumor profiling testing by a Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified, College of American Pathologists-accredited lab is required for patients to enroll in the study.